The material posted on HIV and Hepatitis.com about DDW 2009 is not approved by nor is it a part of DDW 2009.
HOME
Hepatitis C
Hepatitis B
HIV and AIDS
HIV-HCV Coinfection
HIV-HBV Coinfection
About Us
HIV and Hepatitis.com Coverage of
Digestive Disease Week (
DDW 2009
)
-
May 30 - June 4, 2009, Chicago, Illinois
Library of Slides and Posters
Hepatitis B Articles
Hepatitis C Articles
HIV-HCV or HIV-HBV Coinfection Articles
Sign up to receive our
twice-weekly e-Newsletter
Library of Slides and Posters
Hepatitis B Slides and Posters
Entecavir (ETV)
Therapy in Chronic Hepatitis B Patients Previously Treated with
Adefovir (ADV)
with Incomplete Response On-Treatment or Relapse Off-Treatment
N Leung and others. DDW 2009.
Long-Term Histological Improvement with
Entecavir (ETV)
Therapy in Patients with Chronic Hepatitis B (CHB) from Japanese and Worldwide Development Programs
Y Liaw and others. DDW 2009.
Entecavir
Maintains a High Genetic Barrier to HBV Resistance Through 6 Years in Naïve Patients
D Tenney and others. DDW 2009.
Regression of Fibrosis/Cirrhosis with Long-Term
Entecavir
Therapy in Chronic Hepatitis B (CHB) Patients with Baseline Bridging Fibrosis or Cirrhosis: Results from Studies ETV-022, -027 and -901
E Schiff and others. DDW 2009.
Association between HBV Replication and Serum ALT Changes is not Dependent on HBV Genotype and Mutants
H Yang and others. DDW 2009.
Risk and Predictors of HCC in People Less than 40 years of Age: Update from the R.E.V.E.A.L.-HBV Study
C Chen and others. DDW 2009.
Hepatitis C Slides and Posters
HIV-HCV Coinfected and
HCV Monoinfected
Patients with Genotype 2-3 Respond Equally Well to 24 Weeks of Pegylated Interferon plus Ribavirin
Top
Hepatitis C Articles
Many People with Chronic Hepatitis B and C
Do Not Receive Appropriate Treatment
6
-
16
-
2009
Older Genotype 3 Chronic Hepatitis C Patients Do Not Respond as Well to
Interferon-based Therapy
6
-
16
-
2009
Asian-American Chronic Hepatitis C Patients Respond Well to
Pegylated Interferon plus Ribavirin
6
-
12
-
2009
Asian-Americans Are More Likely to Have
Unknown Hepatitis C Virus Transmission Risk Factors
6
-
12
-
2009
Metabolic Syndrome Is Associated with Increased Risk of
Hepatocellular Carcinoma
in Chronic Hepatitis C Patients
6
-
9
-
2009
Strategies for Managing
Acetaminophen-related Liver Disease
and Acute Liver Failure
6
-
5
-
2009
Vitamin B12 Levels May Help Predict Response to
Interferon-based Therapy
for Chronic Hepatitis C
6
-
5
-
2009
Top
Hepatitis B Articles
Predictors of Sustained Treatment Response in
HIV-HCV Coinfected Patients
Receiving Routine Care
6
-
16
-
2009
Many People with Chronic Hepatitis B and C
Do Not Receive Appropriate Treatment
6
-
16
-
2009
Hepatitis B Prevalence and Susceptibility
among Immigrant and U.S.-born Asians and Pacific Islanders
6
-
12
-
2009
High HBV DNA Leve
l Is the Strongest Predictor of Elevated ALT
6
-
9
-
2009
Should
Entecavir (Baraclude) and Tenofovir (Viread)
Be First-line Treatment for Chronic Hepatitis B?
6
-
5
-
2009
Slides and Posters on
Entecavir (Baraclude)
and Hepatitis B Liver Disease Progression Presented at DDW 2009
6
-
5
-
2009
Top
HIV-HCV or HIV-HBV Coinfection Articles
Does
HIV-HCV Coinfection
Increase the Risk of Liver Disease Progression and Worsen Clinical Outcomes?
6
-
9
-
2009
HIV-HCV Coinfected
and HCV Monoinfected Patients with Genotype 2-3 Respond Equally Well to 24 Weeks of Pegylated Interferon plus Ribavirin
FDA-approved Combination Therapies for Chronic HCV Infection
Pegasys + Copegus
PEG-Intron + Rebetol
Intron A + Rebetol
Roferon A + Ribavirin
FDA-approved Therapies for Chronic HBV Infection
Baraclude
(entecavir)
Epivir-HBV
(lamivudine; 3TC)
Hepsera
(
adefovir dipivoxil)
Intron A
(interferon alfa-2b)
Pegasys
(peginterferon alfa-2a)
Viread
(tenofovir)
Tyzeka
(telbivudine)
HIV and Hepatitis.com
is published by
HIV and Hepatitis Treatment Advocates, Inc
.
